CCM
PLRX icon

Coldstream Capital Management’s Pliant Therapeutics PLRX Stock Holding History

Coldstream Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,061
Closed -$4.13K – 2739
2025
Q1 		$4.13K Buy
+3,061
New +$18.6K ﹤0.01% 2781

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Coldstream Capital Management's PLRX Position: Q2 2025 in Review

Coldstream Capital Management sold out of Pliant Therapeutics (PLRX) in Q2 2025, closing a stake of 3,061 shares — an estimated $4.13K sold.

Coldstream Capital Management first reported a position in PLRX in Q1 2025 and held it in 1 quarter. The position peaked at $4.13K in Q1 2025. 114 funds tracked by Wall St. Rank hold PLRX as of Q2 2025.

  • Coldstream Capital Management reported no remaining Pliant Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 3,061 Pliant Therapeutics shares in Q2 2025, an estimated $4.13K.
  • Coldstream Capital Management first reported a position in Pliant Therapeutics in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Pliant Therapeutics position peaked at $4.13K in Q1 2025.
  • 114 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.